Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate Dose Enoxaparin in Moderate-Severe COVID-19
NCT04427098Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by Sant'Orsola-Malpighi University Hospital. Started May 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04427098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427098.